Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Conditions
Interventions
Intervention1: Drug: Aspirin 150 mg PO daily along with the standard of care
Control Intervention1: Standard of Care: Standard of care as per the stage of the disease and guidelines ie Surgery, Chemot
Sponsors
Department of Surgical Oncology
Eligibility
Inclusion criteria
Inclusion criteria: All Histologically proven cases of primary cervical cancers. Stage I to IV Karnofsky’s performance more than 70 ECOG 0 to 2 Hb more than 8.0 gm/dL Total count more than 4000 cells/ml Platelet count more than 100000 cells/ml Serum creatinine less than 1.0mg/ml Liver enzymes up to 1.5 times normal Bilirubin less than 1.0mg/ml
Exclusion criteria
Exclusion criteria: acid peptic disease Pregnancy and ongoing lactation Unwilling to participat NSAID allergy Asthma, rhinitis and nasal polyps Viral fever Use of other blood thinners Bleeding/blood-clotting disorders (such as hemophilia, vitamin K deficiency, low platelet count) pyruvate kinase or G6PD deficiency Patients receiving mifepristone, acetazolamide, corticosteroids, dichlorphenamide, methotrexate, valproic acid Recent anti-viral vaccines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (a)Progression Free Survival (b)Disease Free Survival Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of aspirin in cervical cancer patientsTimepoint: 1 year | — |
Countries
India
Contacts
Public ContactAkshay Kantha
Institute of Medical Sciences, BHU
Outcome results
None listed